Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Overcoming Challenges in Process Development of Cellular Therapies.

Highfill SL, Stroncek DF.

Curr Hematol Malig Rep. 2019 Aug;14(4):269-277. doi: 10.1007/s11899-019-00529-5. Review.

PMID:
31278568
2.

Effect of Cryopreservation on Autologous Chimeric Antigen Receptor T Cell Characteristics.

Panch SR, Srivastava SK, Elavia N, McManus A, Liu S, Jin P, Highfill SL, Li X, Dagur P, Kochenderfer JN, Fry TJ, Mackall CL, Lee D, Shah NN, Stroncek DF.

Mol Ther. 2019 Jul 3;27(7):1275-1285. doi: 10.1016/j.ymthe.2019.05.015. Epub 2019 May 30.

PMID:
31178392
3.

Modulation of Target Antigen Density Improves CAR T-cell Functionality and Persistence.

Ramakrishna S, Highfill SL, Walsh Z, Nguyen SM, Lei H, Shern JF, Qin H, Kraft IL, Stetler-Stevenson M, Yuan CM, Hwang JD, Feng Y, Zhu Z, Dimitrov D, Shah NN, Fry TJ.

Clin Cancer Res. 2019 Sep 1;25(17):5329-5341. doi: 10.1158/1078-0432.CCR-18-3784. Epub 2019 May 20.

PMID:
31110075
4.

Effects of starting cellular material composition on chimeric antigen receptor T-cell expansion and characteristics.

Elavia N, Panch SR, McManus A, Bikkani T, Szymanski J, Highfill SL, Jin P, Brudno J, Kochenderfer J, Stroncek DF.

Transfusion. 2019 May;59(5):1755-1764. doi: 10.1111/trf.15287. Epub 2019 Apr 11.

PMID:
30973976
5.

Production of a cellular product consisting of monocytes stimulated with Sylatron® (Peginterferon alfa-2b) and Actimmune® (Interferon gamma-1b) for human use.

Green DS, Nunes AT, Tosh KW, David-Ocampo V, Fellowes VS, Ren J, Jin J, Frodigh SE, Pham C, Procter J, Tran C, Ekwede I, Khuu H, Stroncek DF, Highfill SL, Zoon KC, Annunziata CM.

J Transl Med. 2019 Mar 14;17(1):82. doi: 10.1186/s12967-019-1822-6.

6.

Single cell sequencing reveals gene expression signatures associated with bone marrow stromal cell subpopulations and time in culture.

Liu S, Stroncek DF, Zhao Y, Chen V, Shi R, Chen J, Ren J, Liu H, Bae HJ, Highfill SL, Jin P.

J Transl Med. 2019 Jan 11;17(1):23. doi: 10.1186/s12967-018-1766-2.

7.

A Phase 1 trial of autologous monocytes stimulated ex vivo with Sylatron® (Peginterferon alfa-2b) and Actimmune® (Interferon gamma-1b) for intra-peritoneal administration in recurrent ovarian cancer.

Green DS, Nunes AT, David-Ocampo V, Ekwede IB, Houston ND, Highfill SL, Khuu H, Stroncek DF, Steinberg SM, Zoon KC, Annunziata CM.

J Transl Med. 2018 Jul 16;16(1):196. doi: 10.1186/s12967-018-1569-5.

8.

Enhanced clinical-scale manufacturing of TCR transduced T-cells using closed culture system modules.

Jin J, Gkitsas N, Fellowes VS, Ren J, Feldman SA, Hinrichs CS, Stroncek DF, Highfill SL.

J Transl Med. 2018 Jan 24;16(1):13. doi: 10.1186/s12967-018-1384-z.

9.

Reduction of MDSCs with All-trans Retinoic Acid Improves CAR Therapy Efficacy for Sarcomas.

Long AH, Highfill SL, Cui Y, Smith JP, Walker AJ, Ramakrishna S, El-Etriby R, Galli S, Tsokos MG, Orentas RJ, Mackall CL.

Cancer Immunol Res. 2016 Oct;4(10):869-880. Epub 2016 Aug 22.

10.

Activation of Hematopoietic Stem/Progenitor Cells Promotes Immunosuppression Within the Pre-metastatic Niche.

Giles AJ, Reid CM, Evans JD, Murgai M, Vicioso Y, Highfill SL, Kasai M, Vahdat L, Mackall CL, Lyden D, Wexler L, Kaplan RN.

Cancer Res. 2016 Mar 15;76(6):1335-47. doi: 10.1158/0008-5472.CAN-15-0204. Epub 2015 Dec 30.

11.

Nfatc2 and Tob1 have non-overlapping function in T cell negative regulation and tumorigenesis.

May SL, Zhou Q, Lewellen M, Carter CM, Coffey D, Highfill SL, Bucher CM, Matise I, Morse HC 3rd, O'Sullivan MG, Schutten M, Johnson C, Bellgrau D, Blazar BR, Modiano JF.

PLoS One. 2014 Jun 19;9(6):e100629. doi: 10.1371/journal.pone.0100629. eCollection 2014.

12.

Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy.

Highfill SL, Cui Y, Giles AJ, Smith JP, Zhang H, Morse E, Kaplan RN, Mackall CL.

Sci Transl Med. 2014 May 21;6(237):237ra67. doi: 10.1126/scitranslmed.3007974.

13.

A pan-inhibitor of DASH family enzymes induces immune-mediated regression of murine sarcoma and is a potent adjuvant to dendritic cell vaccination and adoptive T-cell therapy.

Duncan BB, Highfill SL, Qin H, Bouchkouj N, Larabee S, Zhao P, Woznica I, Liu Y, Li Y, Wu W, Lai JH, Jones B, Mackall CL, Bachovchin WW, Fry TJ.

J Immunother. 2013 Oct;36(8):400-11. doi: 10.1097/CJI.0b013e3182a80213.

14.

Bone marrow myeloid-derived suppressor cells (MDSCs) inhibit graft-versus-host disease (GVHD) via an arginase-1-dependent mechanism that is up-regulated by interleukin-13.

Highfill SL, Rodriguez PC, Zhou Q, Goetz CA, Koehn BH, Veenstra R, Taylor PA, Panoskaltsis-Mortari A, Serody JS, Munn DH, Tolar J, Ochoa AC, Blazar BR.

Blood. 2010 Dec 16;116(25):5738-47. doi: 10.1182/blood-2010-06-287839. Epub 2010 Aug 31.

15.

Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia.

Zhou Q, Munger ME, Highfill SL, Tolar J, Weigel BJ, Riddle M, Sharpe AH, Vallera DA, Azuma M, Levine BL, June CH, Murphy WJ, Munn DH, Blazar BR.

Blood. 2010 Oct 7;116(14):2484-93. doi: 10.1182/blood-2010-03-275446. Epub 2010 Jun 22.

16.

Constitutively active Stat5b in CD4+ T cells inhibits graft-versus-host disease lethality associated with increased regulatory T-cell potency and decreased T effector cell responses.

Vogtenhuber C, Bucher C, Highfill SL, Koch LK, Goren E, Panoskaltsis-Mortari A, Taylor PA, Farrar MA, Blazar BR.

Blood. 2010 Jul 22;116(3):466-74. doi: 10.1182/blood-2009-11-252825. Epub 2010 May 4.

17.

Depletion of endogenous tumor-associated regulatory T cells improves the efficacy of adoptive cytotoxic T-cell immunotherapy in murine acute myeloid leukemia.

Zhou Q, Bucher C, Munger ME, Highfill SL, Tolar J, Munn DH, Levine BL, Riddle M, June CH, Vallera DA, Weigel BJ, Blazar BR.

Blood. 2009 Oct 29;114(18):3793-802. doi: 10.1182/blood-2009-03-208181. Epub 2009 Sep 1.

18.

Multipotent adult progenitor cells can suppress graft-versus-host disease via prostaglandin E2 synthesis and only if localized to sites of allopriming.

Highfill SL, Kelly RM, O'Shaughnessy MJ, Zhou Q, Xia L, Panoskaltsis-Mortari A, Taylor PA, Tolar J, Blazar BR.

Blood. 2009 Jul 16;114(3):693-701. doi: 10.1182/blood-2009-03-213850. Epub 2009 May 20.

19.

Keratinocyte growth factor and androgen blockade work in concert to protect against conditioning regimen-induced thymic epithelial damage and enhance T-cell reconstitution after murine bone marrow transplantation.

Kelly RM, Highfill SL, Panoskaltsis-Mortari A, Taylor PA, Boyd RL, Holländer GA, Blazar BR.

Blood. 2008 Jun 15;111(12):5734-44. doi: 10.1182/blood-2008-01-136531. Epub 2008 Mar 11.

20.

Deregulated expression of LRBA facilitates cancer cell growth.

Wang JW, Gamsby JJ, Highfill SL, Mora LB, Bloom GC, Yeatman TJ, Pan TC, Ramne AL, Chodosh LA, Cress WD, Chen J, Kerr WG.

Oncogene. 2004 May 20;23(23):4089-97.

PMID:
15064745

Supplemental Content

Loading ...
Support Center